More than 1000 antibodies targeting the PD-1/PD-L1 pathway have been evaluated in clinical trials and are approved for use in a variety of malignancies, such as melanoma [6], non-small cell lung cancer [7], renal cell carcinoma, etc. [8]. This evidence concerns the gene PDCD1 and melanoma.